Mednet Reports

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - American Heart Association (AHA) Scientific Sessions 2014

Lower Is Better: New Data Confirm the LDL Hypothesis as New Options Are Identified for Improved Control

Chicago, Illinois / November 15-19, 2014

Chicago - New evidence of a cardiovascular (CV) benefit from lipid-lowering therapy with a non-statin has extended the lipid hypothesis, expanding opportunities for risk reduction. One of the trials presented at the 2014 Scientific Sessions...

PRIORITY PRESS - 11th Canadian Immunization Conference

Influenza in the Elderly: Seeking More Effective Vaccine Strategies

Ottawa, Ontario / December 2-4, 2014

Ottawa - Elderly patients are at high risk for developing influenza and its complications, which can include increased frailty after hospitalization. Immunization in this population is vital, despite the fact that immune senescence lowers...

PRIORITY PRESS - 11th Canadian Immunization Conference

Expanding Protection against Influenza in the Most Vulnerable: Focus on Adjuvanted Influenza Vaccines

Ottawa, Ontario / December 2-4, 2014

Ottawa – The burden of illness associated with influenza infection is considerable, and it is particularly pronounced in the very young and in the elderly. Both groups respond less than optimally to standard influenza vaccines and...

PRIORITY PRESS - 11th Canadian Immunization Conference

Integrating the New Meningococcal B Vaccine into Clinical Practice: Lessons From the Experts

Ottawa, Ontario / December 2-4, 2014

Ottawa – Of the 5 serogroups responsible for invasive meningococcal disease (IMD), serogroup B is by far the most common in Canada today.  IMD also disproportionately affects young infants with another peak in incidence in...

PRIORITY PRESS - 56th Annual Meeting of the American Society of Hematology (ASH)

Selecting Second- and Third-Line TKIs in CML: Offering Tolerability in the Context of Indefinite Disease Control

San Francisco, California / December 6-9, 2014

San Francisco - A focus on the relative long-term safety and tolerability of available tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has been intensified by the evidence that drugs in this class, when...

PRIORITY PRESS - 11th Canadian Immunization Conference

A Primer on HPV Vaccination for Primary Care Practitioners: NACI Recommendations Should Prevail

Ottawa, Ontario / December 2-4, 2014

Ottawa - Primary care providers are required to answer three questions for patients when they come asking about the human papilloma virus (HPV) vaccine: Is it safe? Does it work? And what do you think about it? Providing good,...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the American Heart Association (AHA) 2014 Scientific Sessions

IMPROVE-IT: Reaffirmation of Lipid Hypothesis By Non-Statin Ezetimibe in High-Risk Population

Chicago, Illinois / November 15-19, 2014

Guest Editor: Dr. Paul W. Armstrong, MD, FCAHS, FRSCDistinguished University ProfessorMazankowski Alberta Heart InstituteUniversity of AlbertaEdmonton, Alberta Dr. Armstrong served on the Steering Committee of IMPROVE-IT and was one of...

PRIORITY PRESS - Canadian Cardiovascular Congress (CCC)

The LDL-C Treatment Gap Expected to Be Essentially Closed with New Lipid-Lowering Agents

Vancouver, BC / October 25-28, 2014

Vancouver - Lipid-lowering therapies now in late stages of development are expected to bring the majority of patients to guideline-recommended treatment goals regardless of the reason why they are unable to reach their goal on current...

PRIORITY PRESS - 39th Annual Congress of the European Society for Medical Oncology (ESMO)

Survival Data Justify Early Use of Androgen Pathway Inhibitor in Metastatic Castration Resistant Prostate Cancer

Madrid, Spain / September 26-30, 2014

Madrid - The final overall survival (OS) results of a phase 3 multicentre trial have confirmed the value of first-line androgen inhibition in metastatic castration resistant prostate cancer (mCRPC). In the study, early use of an androgen...

PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)

Objective Response to a TKI in Metastatic Renal Cell Cancer Is Substantially Improved with Individualized Dose Schedules

Madrid, Spain / September 26-30, 2014

Madrid - Optimal response to a tyrosine kinase inhibitor (TKI) employed first line in metastatic renal cell carcinoma (mRCC) appears to be achieved by individualizing the dose and schedule in order to sustain dose intensity, according to...

PAGE 5 OF 110   1 2 3 4 5 6 7 8 9 10 ...